All Photos(1)

Pr8/22

93112518

biological source

mouse lymph

growth mode

Suspension

karyotype

Not specified

morphology

Not specified

products

Not specified

receptors

Not specified

technique(s)

cell culture | mammalian: suitable

relevant disease(s)

cancer

shipped in

dry ice

storage temp.

−196°C

Related Categories

Cell Line Origin

Mouse DBA/2 lymphoid neoplasm derivative; drug resistant

Cell Line Description

The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm originating in DBA/2 mouse and converted to ascitic form in the first mouse transfer. Pr8/22 is resistant to daunorubicin and is multi drug resistant (MDR). Cells should be treated with the drug at least once a month and before freezing, however after resuscitating daunorubicin should not be added until the first passage. It is advisable to keep a backup culture which is not drug-challenged.

Application

Study of drug-resistance

Culture Medium

RPMI 1640 + 2mM Glutamine + 10% Horse Serum (HS); treat once a month with 0.1μM Daunorubicin

Subculture Routine

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Disclaimer

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.

Certificate of Analysis

Certificate of Origin

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service